To support this, we demonstrated that CSF2RB knockdown decreased proliferation in human AML cell lines expressing FLT3-ITD and in xenograft experiments, led to reduced disease burden and increased survival. This evidence concerns the gene FLT3 and acute myeloid leukemia.